We found significantly higher concentrations of APRIL and BAFF in ET patients when compared to healthy controls, regardless of the presence of the JAK2(V617F) mutation (Figure 2A,B, respectively). The gene discussed is TNFSF13; the disease is essential thrombocythemia.